Biomea Fusion, Inc. (BMEA): Total Liabilities
$29.02M
As of 2025-12-31
$24.74M
As of 2026-06-30
+11.8%
3-year compound annual growth
+78.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $29.02M | +2.3% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $28.36M | -7.6% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $30.69M | +47.8% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $20.77M | +200.0% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $6.92M | +327.5% | 2023-03-28, Balance as of period end |
| 2020-12-31 | $1.62M | n/a | 2022-02-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | $29.02M | +2.3% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $17.11M | -48.4% |
| Scynexis Inc (SCYX) | 2025-12-31 | $9.65M | -72.9% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $33.06M | -3.2% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $31.58M | +23.2% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $56.36M | +0.9% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $20.16M | -24.3% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $5.02M | +291.6% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $30.24M | -28.7% |
Compare BMEA, RANI, SCYX, ALXO side by side · Screen every company in Pharmaceutical Preparations ↗